CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC-1295 NO DAC (Mod GRF 1-29) 5mg – High-Purity Research Peptide

CJC-1295 NO DAC, universally recognized in scientific literature as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic, tetrasubstituted 29-amino-acid peptide derived from natural Growth Hormone-Releasing Hormone (GHRH). Engineered with four target amino acid substitutions (positions 2, 8, 15, and 27), this compound exhibits high enzymatic resistance against cleavage while maintaining a physiological, short-acting pulsatile release profile. Each vial contains 5mg of high-purity (>99% HPLC and Mass Spectrometry verified) lyophilized powder intended strictly for laboratory and in vitro research applications.

Structural Modifications & Molecular Mechanism

Natural GHRH 1-29 (Sermorelin) possesses a short biological half-life (\approx 7–10 minutes) due to rapid inactivation by the enzyme dipeptidyl peptidase-IV (DPP-IV). Mod GRF 1-29 addresses this issue through four strategic amino acid substitutions:  

 Position 2 (D-Alanine): Inhibits DPP-IV enzymatic cleavage at the N-terminal active site.

 Position 8 (Glutamine): Prevents unwanted cyclic imide degradation pathways.

 Position 15 (Alanine): Enhances structural stability and bioactive binding affinity.  

 Position 27 (Leucine): Replaces oxidation-sensitive methionine to improve shelf stability.

Unlike the long-acting CJC-1295 DAC variant, Mod GRF 1-29 lacks the Drug Affinity Complex (DAC). It does not bind serum albumin, producing a short operational half-life (\approx 30 minutes). This allows researchers to stimulate pituitary somatotroph cells in natural, pulsatile spikes without causing continuous, unnatural GH elevation.  

Key Laboratory Research Applications

 Somatotroph Receptor Kinetics: Utilized to observe Class B G-protein-coupled receptor (GHRHR) binding, downstream cAMP intracellular activation, and protein kinase A (PKA) signaling cascades.  

 Pulsatile vs. Continuous GH Axis Models: Serves as a primary control compound to contrast short-burst pulsatile endocrine stimulation against long-acting GHRH variants.

 Dual-Pathway Synergy Studies: Frequently evaluated alongside ghrelin-receptor agonists (e.g., Ipamorelin) to analyze dual GHRH/GHS-R pathway amplification.

 IGF-1 Downstream Gene Expression: Employed in cell line models to investigate systemic insulin-like growth factor 1 (IGF-1) transcription and nitrogen balance mechanisms.  

Storage, Reconstitution & Handling Protocols

 Lyophilized Powder: Store unopened vials at -20^\circ\text{C} in a dry, dark place. Material remains stable at ambient temperature during standard transit.  

 Reconstitution Procedure: Bring the vial to room temperature prior to diluent introduction. Reconstitute using bacteriostatic water or sterile lab-grade saline. Direct fluid down the inner wall of the vial and swirl gently—do not vortex or agitate vigorously.  

Reconstituted Solution: Maintain at 2^\circ\text{C} to 8^\circ\text{C}. Use in single-use aliquots where applicable to avoid repeated freeze-thaw degradation cycles.  

Quality Assurance & Research Compliance

Every batch of CJC-1295 NO DAC 5mg undergoes rigorous testing via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify molecular weight and chemical purity. A batch-specific Certificate of Analysis (COA) is provided upon request.  

Laboratory Research Use Only Disclaimer

This product is distributed strictly for laboratory research, in vitro studies, and preclinical scientific experimentation. It is not intended for human or animal therapeutic use, clinical trials, cosmetic applications, or medical diagnosis. All handling must be performed by certified scientific personnel inside appropriately equipped research facilities.